264 related articles for article (PubMed ID: 26634982)
1. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
3. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
4. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.
Reindl W; Gräber M; Strebhardt K; Berg T
Anal Biochem; 2009 Dec; 395(2):189-94. PubMed ID: 19716361
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
6. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
7. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
8. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
Zhao XZ; Tsuji K; Hymel D; Burke TR
Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.
Baxter M; Chapagai D; Craig S; Hurtado C; Varghese J; Nurmemmedov E; Wyatt MD; McInnes C
ChemMedChem; 2020 Jun; 15(12):1058-1066. PubMed ID: 32232973
[TBL] [Abstract][Full Text] [Related]
11. Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.
Scharow A; Raab M; Saxena K; Sreeramulu S; Kudlinzki D; Gande S; Dötsch C; Kurunci-Csacsko E; Klaeger S; Kuster B; Schwalbe H; Strebhardt K; Berg T
ACS Chem Biol; 2015 Nov; 10(11):2570-9. PubMed ID: 26279064
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
Chen Y; Li Z; Liu Y; Lin T; Sun H; Yang D; Jiang C
Bioorg Chem; 2018 Dec; 81():278-288. PubMed ID: 30170276
[TBL] [Abstract][Full Text] [Related]
13. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1.
Li Z; Zhang Z; Sun H; Xu L; Jiang C
Bioorg Chem; 2019 Oct; 91():103148. PubMed ID: 31376784
[TBL] [Abstract][Full Text] [Related]
15. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
Yun T; Qin T; Liu Y; Lai L
Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors.
Lin TY; Min HP; Jiang C; Niu MM; Yan F; Xu LL; Di B
Bioorg Med Chem; 2018 Jul; 26(12):3429-3437. PubMed ID: 29807699
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
